1159 related articles for article (PubMed ID: 29018234)
1. Homo-PROTACs: bivalent small-molecule dimerizers of the VHL E3 ubiquitin ligase to induce self-degradation.
Maniaci C; Hughes SJ; Testa A; Chen W; Lamont DJ; Rocha S; Alessi DR; Romeo R; Ciulli A
Nat Commun; 2017 Oct; 8(1):830. PubMed ID: 29018234
[TBL] [Abstract][Full Text] [Related]
2. Cereblon versus VHL: Hijacking E3 ligases against each other using PROTACs.
Girardini M; Maniaci C; Hughes SJ; Testa A; Ciulli A
Bioorg Med Chem; 2019 Jun; 27(12):2466-2479. PubMed ID: 30826187
[TBL] [Abstract][Full Text] [Related]
3. Discovery of small molecule ligands for the von Hippel-Lindau (VHL) E3 ligase and their use as inhibitors and PROTAC degraders.
Diehl CJ; Ciulli A
Chem Soc Rev; 2022 Oct; 51(19):8216-8257. PubMed ID: 35983982
[TBL] [Abstract][Full Text] [Related]
4. E3 Ligase Ligands for PROTACs: How They Were Found and How to Discover New Ones.
Ishida T; Ciulli A
SLAS Discov; 2021 Apr; 26(4):484-502. PubMed ID: 33143537
[TBL] [Abstract][Full Text] [Related]
5. Journey of Von Hippel-Lindau (VHL) E3 ligase in PROTACs design: From VHL ligands to VHL-based degraders.
Setia N; Almuqdadi HTA; Abid M
Eur J Med Chem; 2024 Feb; 265():116041. PubMed ID: 38199162
[TBL] [Abstract][Full Text] [Related]
6. Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase.
Smith BE; Wang SL; Jaime-Figueroa S; Harbin A; Wang J; Hamman BD; Crews CM
Nat Commun; 2019 Jan; 10(1):131. PubMed ID: 30631068
[TBL] [Abstract][Full Text] [Related]
7. Chemical approaches to targeted protein degradation through modulation of the ubiquitin-proteasome pathway.
Collins I; Wang H; Caldwell JJ; Chopra R
Biochem J; 2017 Mar; 474(7):1127-1147. PubMed ID: 28298557
[TBL] [Abstract][Full Text] [Related]
8. PROTAC-mediated crosstalk between E3 ligases.
Steinebach C; Kehm H; Lindner S; Vu LP; Köpff S; López Mármol Á; Weiler C; Wagner KG; Reichenzeller M; Krönke J; Gütschow M
Chem Commun (Camb); 2019 Feb; 55(12):1821-1824. PubMed ID: 30672516
[TBL] [Abstract][Full Text] [Related]
9. VHL-based PROTACs as potential therapeutic agents: Recent progress and perspectives.
Wang C; Zhang Y; Wang J; Xing D
Eur J Med Chem; 2022 Jan; 227():113906. PubMed ID: 34656901
[TBL] [Abstract][Full Text] [Related]
10. Discovery of Highly Potent and Efficient PROTAC Degraders of Androgen Receptor (AR) by Employing Weak Binding Affinity VHL E3 Ligase Ligands.
Han X; Zhao L; Xiang W; Qin C; Miao B; Xu T; Wang M; Yang CY; Chinnaswamy K; Stuckey J; Wang S
J Med Chem; 2019 Dec; 62(24):11218-11231. PubMed ID: 31804827
[TBL] [Abstract][Full Text] [Related]
11. Surface Probing by Fragment-Based Screening and Computational Methods Identifies Ligandable Pockets on the von Hippel-Lindau (VHL) E3 Ubiquitin Ligase.
Lucas X; Van Molle I; Ciulli A
J Med Chem; 2018 Aug; 61(16):7387-7393. PubMed ID: 30040896
[TBL] [Abstract][Full Text] [Related]
12. Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity.
Lv D; Pal P; Liu X; Jia Y; Thummuri D; Zhang P; Hu W; Pei J; Zhang Q; Zhou S; Khan S; Zhang X; Hua N; Yang Q; Arango S; Zhang W; Nayak D; Olsen SK; Weintraub ST; Hromas R; Konopleva M; Yuan Y; Zheng G; Zhou D
Nat Commun; 2021 Nov; 12(1):6896. PubMed ID: 34824248
[TBL] [Abstract][Full Text] [Related]
13. Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead.
Bondeson DP; Smith BE; Burslem GM; Buhimschi AD; Hines J; Jaime-Figueroa S; Wang J; Hamman BD; Ishchenko A; Crews CM
Cell Chem Biol; 2018 Jan; 25(1):78-87.e5. PubMed ID: 29129718
[TBL] [Abstract][Full Text] [Related]
14. Exploring the Ubiquitin-Proteasome System (UPS) through PROTAC Technology.
Cecchini C; Tardy S; Ceserani V; Theurillat JP; Scapozza L
Chimia (Aarau); 2020 Apr; 74(4):274-277. PubMed ID: 32331546
[TBL] [Abstract][Full Text] [Related]
15. Targeting the von Hippel-Lindau E3 ubiquitin ligase using small molecules to disrupt the VHL/HIF-1α interaction.
Buckley DL; Van Molle I; Gareiss PC; Tae HS; Michel J; Noblin DJ; Jorgensen WL; Ciulli A; Crews CM
J Am Chem Soc; 2012 Mar; 134(10):4465-8. PubMed ID: 22369643
[TBL] [Abstract][Full Text] [Related]
16. Structure-guided design and optimization of small molecules targeting the protein-protein interaction between the von Hippel-Lindau (VHL) E3 ubiquitin ligase and the hypoxia inducible factor (HIF) alpha subunit with in vitro nanomolar affinities.
Galdeano C; Gadd MS; Soares P; Scaffidi S; Van Molle I; Birced I; Hewitt S; Dias DM; Ciulli A
J Med Chem; 2014 Oct; 57(20):8657-63. PubMed ID: 25166285
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and activity study of a novel PI3K degradation by hijacking VHL E3 ubiquitin ligase.
Wang H; Li C; Liu X; Ma M
Bioorg Med Chem; 2022 May; 61():116707. PubMed ID: 35344835
[TBL] [Abstract][Full Text] [Related]
18. Targeted protein degradation and the enzymology of degraders.
Fisher SL; Phillips AJ
Curr Opin Chem Biol; 2018 Jun; 44():47-55. PubMed ID: 29885948
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and Evaluation of Cereblon-Recruiting HaloPROTACs.
Ody BK; Zhang J; Nelson SE; Xie Y; Liu R; Dodd CJ; Jacobs SE; Whitzel SL; Williams LA; Gozem S; Turlington M; Yin J
Chembiochem; 2023 Nov; 24(21):e202300498. PubMed ID: 37625128
[TBL] [Abstract][Full Text] [Related]
20. Catalytic in vivo protein knockdown by small-molecule PROTACs.
Bondeson DP; Mares A; Smith IE; Ko E; Campos S; Miah AH; Mulholland KE; Routly N; Buckley DL; Gustafson JL; Zinn N; Grandi P; Shimamura S; Bergamini G; Faelth-Savitski M; Bantscheff M; Cox C; Gordon DA; Willard RR; Flanagan JJ; Casillas LN; Votta BJ; den Besten W; Famm K; Kruidenier L; Carter PS; Harling JD; Churcher I; Crews CM
Nat Chem Biol; 2015 Aug; 11(8):611-7. PubMed ID: 26075522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]